A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) Followed by Enzalutamide or Abiraterone Post-BAT in Men With Prostate Cancer Progressing on Combined Androgen Ablative Therapies

Trial Profile

A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) Followed by Enzalutamide or Abiraterone Post-BAT in Men With Prostate Cancer Progressing on Combined Androgen Ablative Therapies

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Testosterone cipionate (Primary) ; Testosterone enanthate (Primary) ; Abiraterone acetate; Enzalutamide
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms RESTORE
  • Most Recent Events

    • 13 Dec 2017 Results (n=30; data cut off: May, 2016) of data representing final analysis of post-enzalutamide cohort, published in the Lancet Oncology.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results (n=30, accrued between year 2014-2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top